Диссертация (1141158), страница 20
Текст из файла (страница 20)
JAffect Dis. 2005;86:1-10.102. Frances A., Docherty J., Kahn D. The expert consensus guideline series:Treatment of bipolar disorder. J Clin Psychiatry. 1996;57:1-88.103. Frances A., Kahn D.A., Carpenter D., Docherty J., Donovan S.L. The expertconsensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry.1998;59(4):73-79.104. Franchini L., Zanardi R., Smeraldi E. et al.
Early onset of lithium prophylaxisas a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci.1999;249:227-230.105. Fresno D., Fountoulakis K., Amann B., Vieta E. Acute and maintenancetreatment of bipolar disorder with second generation antipsychotics: Part 1.
ClinApproaches in Bipolar Disorder. 2006;5(2):45-50.106. Frye M.A., Altshuler L.L., McElroy S.L. et al. Gender differences inprevalence, risk and clinical correlate of alcoholism comorbidity in bipolardisorder. Am J Psychiatry. 2003;160:883-889.107. Frye M.A., Ketter T.A., Kimbrell T.A. et al. A placebo-controlled study oflamotrigine and gabapentin monotherapy in refractory mood disorders. J ClinPsychopharmacol. 2000;20:607-614.108.
Fukuda K., Etoh T., Iwadate T., Ishii A. The course and prognosis of manicdepressive psychosis of episodes and intervals. Exp Med. 1983;139:299-307.109. Gao K.C., Gajwani P., Elhaj O., Calabrese J.R. Typical and atypicalantipsychotics in bipolar depression. J Clin Psychiatry. 2005;66(11):1376-1385.110. Gao K.M.D.P., Kemp D.E.M.D., Ganocy S.J.P. et al. Antipsychotic-inducedextrapyramidal side effects in bipolar disorder and schizophrenia: a systematicreview.
J Clin Psychopharmacol. 2008;28(2):203-209.111. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet.2013;381(9878):1672-1682.120112. Gelenberg A.J., Kane J.M., Keller M.B. Comparison of standard and low serumlevels of lithium for maintenance treatment of bipolar disorders. N Engl J Med.1989;321:1489-1493.113. Gershon F.S., Hamovit J., Guroff J.J. et al. A family study of schizoaffective,bipolar I, bipolar II, unipolar and norm control probands. Arch Gen Psychiatry.1982;39:1157-1167.114. Ghaemi S.N., Gilmer W.S., Goldberg J.F. et al.
Divalproex in the treatment ofacute bipolar depression: a preliminary double-blind, randomized, placebocontrolled pilot study. J Clin Psychiatry. 2007;68(12):1840-1844.115. Ghaemi S.N., Ko J.Y., Goodwin F.K. The bipolar spectrum and theantidepressant view of the world. J Psychiatr Pract. 2001;7:287-297.116. Gijsman H.J., Geddes J.R., Rendell J.M. el al. Antidepressants for bipolardepression: a systematic review of randomized, controlled trials.
Am J Psychiatry.2004;161:1537-1547.117. Gillin J.C., Duncan W.C., Pettigrew K.D. et al. Successful separation ofdepressed, normal and insomniac subjects by EEG sleep data. Arch Gen Psychiat.1979;36:85-90.118. Goldberg J. Spontaneous depression versus biphasic cycling. Am J Psychiatry.2001;158:124-126.119. Goldberg J.F., Truman C.J. Antidepressant-induced mania: an overview ofcurrent controversies. Bipolar Disord. 2003;5:407-420.120. Goldberg J.F., Ernst C.L.
Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985991.121. Goodwin F.K., Jamison К. Manic-Depressive Illness. New York: OxfordUniversity Press, 1990.122. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder:Recommendations from the British Association for Psychopharmacology. JPsychopharmacol. 2003;17:149-173.121123. Grunze H.
et al. World Federation of Societies of Biological PsychiatryGuidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment ofBipolar Depression. World J Biol Psychiatry. 2002;3:115-124.124. Gyulai L., Bowden C.L., McElroy S.L. et al. Maintenance efficacy of divalproexinthepreventionofbipolardepression.Neuropsychopharmacology.2003;28:1374-1382.125. Hantouche E.G., Akiskal H.S., Lancrenon S. et al. Systematic clinicalmethodology for validating bipolar II disorder.
J Affect Disord. 1998;50:163-173.126. Hirschfeld R.M. The unrecognized side of bipolar disorder. Am J Psychiatry.2013;170(8):815-817.127. Hirschfeld R.M., Lewis L., Vornik L.A. Perceptions and impact of bipolardisorder: How far have we really come? J Clin Psychiatry. 2003;64:161-174.128. Hirschfeld R.M., Calabrese J.R., Weissman M.M., Reed M., Davies M.A., FryeM.A., Keck P.E. Jr., Lewis L., McElroy S.L., McNulty J.P., Wagner K.D.Screening for bipolar disorder in the community.
J Clin Psychiatry.2003;64(1):53-59.129. Hirschfeld R.M.A. Guideline watch (November 2005): practice guideline for thetreatment of patients with bipolar disorder, 2nd edition. Focus 2007;5(1):34-39.130. Jamison K.R.. Suicide and bipolar disorder. J Clin Psychiatry.
2000;61(9):4751. Review.131. Joffe R.T., MacQueen G.M., Marriott M. et al. A prospective, longitudinal studyof percentage of time spent ill in patients with bipolar І or bipolar 2 disorders.Bipolar Dis. 2004;6:62-66.132. Judd L.L., Akiskal H.S. The prevalence and disability of bipolar spectrumdisorders in the US population: re-analysis of the ECA database taking intoaccount subthreshold cases.
J Affect Dis. 2003;73:123-131.133. Judd L.L., Akiskal H.S., Schlettler P.J. et al. The long-term natural history ofthe weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry.2002;59:530-537.122134. Kahn D.A., Carpenter D., Docherty J.P., Frances A. The Expert ConsensusGuidelineSeries:TreatmentofBipolarDisorder.JClinPsychiatry.1996;57(suppl12A):1-88.135. Keck P.E. Jr. Bipolar depression: a new role for atypical antipsychotics? BipolarDisord.
2003;5:421-433.136. Keller M.B., Lavori P.W., Coryell W. et al. Differential outcome of pure manic,mixed/cycling and pure depressive episodes in patients with bipolar illness.JAMA. 1986;255:3138-3142.137. Kessler R.C., Crum R.M., Warner L.A., Nelson C.B., Schulenberg J., AnthonyJ.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence withother psychiatric disorders in the National Comorbidity Survey. Arch GenPsychiatry. 1997;54(4):313-321.138.
Kessler R.C., McGonagle K.A., Zhao S. et al. Lifetime and 12-monthprevalence of DSM-III-R psychiatric disorders in the United States: Results fromthe National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.139. Kessler R.C., Stang P., Wittchen H.U. et al. Lifetime co-morbidities betweensocial phobia and mood disorders in the US National Comorbidity Survey.Psychol Med. 1999;29:555-567.140. Ketter T.A., Calabrese J.R. Stabilization of mood from below versus abovebaseline in bipolar disorder: a new nomenclature.
J Clin Psychiatry. 2002;63:146151.141. Kogan J.N., Otto M.W., Bauer M.S. et al. Demographic and diagnosticcharacteristics of the first 1000 patients enrolled in the Systematic TreatmentEnhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2004.142. Kraepelin E. Manic-depressive insanity and paranoia.
Edinburgh: E&S.Livingstone, 1921.143. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: LivingstoneLtd., Reprinted Arno Press. N.Y., 1976.123144. Kukopulos A., Reginaldi D., Laddomada G. et al. Course of the manicdepressive cycle and changes caused by treatments. Pharmacopsychiatr.1980;13:156-167.145. Kupfer D.J. Bipolar depression. The clinician’s reference guide (BD-CRG),Moutva, N.J.
Current Psychiatry, 2004. 96 p.146. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA.2005;293(20):2528-2530.147. Kupfer D.J., Frank E. Trends in diagnosis and treatment of bipolar disorders.Medicographia. 2005;27(3):254-260.148. Kupfer D.J., Frank E., Grochocinski V.J. et al. Stabilization in the treatment ofmania, depression and mixed states. Acta Neuropsychiatrics. 2000;12:110-114.149. Kupka R.W. Rapid cycling. Discrimination factors in rapid and non rapidcycling bipolar disorder. Thesis. University of Utrecht Press, 2003.150. Kupka R.W., Altshuler L.L., Nolen W.A., Suppes T., Luckenbaugh D.A.,Leverich G.S., Frye M.A., Keck P.E. Jr., McElroy S.L., Grunze H., Post R.M..Three times more days depressed than manic or hypomanic in both bipolar I andbipolar II disorder.
Bipolar Disord. 2007;9(5):531-535.151. Lambert P.A. Acute and prophylactic therapies of patients with affectivedisorders using valpromide (dypropylaetamide). In: Anticonvulsants in affectivedisorders (edited by H.E. Emrich), T. Oku-ma, A.A. Muller. Elsevier SciencePublishers. Amsterdam, Oxford, Princeton, 1984.152. Leibenluft E. Women with bipolar illness: Clinical and research issues. Am JPsychiatry. 1996;153:163-173.153. Leverich G.S., Altshuler L.L., Frye M.A. et al. Factors associated with suicideattempts in 648 patients with bipolar disorder in Stanley Foundation BipolarNetwork.
J Clin Psychiatry. 2003;64:506-515.154. Lish J.D., Dime-Meenan S., Whybrow P.C. et al. The national Depressive andManic-Depressive Association (DMDA) survey of bipolar members. J AffectDisord. 1994;31(4):281-294.124155. Maj M., Magliano L., Pirozzi R. et al. Validity of rapid cycling as a coursespecifier for bipolar disorder. Am J Psychiatry. 1994;151:1015-1019.156. Malhi G.S., Adams D., Cahill C.M. et al. The Management of Individuals withBipolar Disorder. Drugs.
2009;69(15):2063-2101.157. Malhi G.S., Mitchell P.B., Salim S. Bipolar Depression. Management options.CNS Drugs. 2003;17(Suppl1):9-25.158. Malhi G.S., Vieta E. Topics in contemporary psychiatric practice diagnosingbipolar disorder. Int J Psych Clin Pract. 2001;5(3):223-224.159. Manning J.S., Haykal R.F., Connor P.D., Akiskal H.S. On the nature ofdepressive and anxious states in a family practice setting: the high prevalence ofbipolar II and related disorders in a cohort followed longitudinally. ComprPsychiatry.
1997;38(2):102-108.160. McElroy S.L., Keck P.E. Jr., Pope H.G. Jr. et al. Valproate in psychiatricdisorders: literature review and clinical guidelines. J Clin Psychiatry.1989;50(3):23-29.161. McElroy S.L., Weisler R.H., Chang W. et al. A double-blind, placebocontrolled study of quetiapine and paroxetine as monotherapy in adults withbipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163–174.162. Mclntyre R.S., Mancini D.A., McCann S.
et al. Topiramate versus bupropionSR when added to mood-stabilizer therapy for the depressive phase of bipolardisorder: a preliminary single-blind study. Bipolar Disord. 2002;4(3):207-213.163. Miller-Siecheneder F., Miller M.J., Hillert A., Szegedu A., Wetzel H., BenkertO. Risperidone versus haloperidol in the treatment of patients with a combinedpsychotic and depressive syndrome. J Clin Psychopharmacol. 1998;18:111-120.164.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
